Insulin Therapy Center

In Part 5 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the potential effect of the proper storage of insulin within the liver on the overall weight of the patient. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In …

In Part 4 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, understanding the best insulin for the admixture and the possible effect on A1C. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the management and strategic …

In Part 3 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the focus on the phase of trials. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the management and strategic direction of …

In Part 2 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the effect of insulin on the liver. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the management and strategic direction of …

In Part 1 of this Exclusive Interview, Dr. Robert Geho joins Diabetes in Control publisher Steve Freed at the 2016 Diabetes Symposium in Boston to discuss a new drug delivery system designed to deliver insulin molecules that are currently sold as commercial insulins to cells in the liver. Robert Geho, …

College student, type 1 diabetes, wears a pump and CGM. She has good family support. Several of her family members get her CGM readings on their phone. She received a call from her mother about 2:45 am waking her up. She told her to treat her low blood glucose, which patient reported to be 41.

Starting patients diagnosed within the last 7 years on 2-4 weeks of intensive insulin therapy could help keep them off additional medications for at least 48 weeks.

It is not unusual for people to have difficulty keeping insulin from freezing or getting overheated. A patient, with type 1 diabetes for 17 years, had glucose that did not respond to his rapid-acting insulin as it usually does. He had two new vials in the refrigerator. He took a new vial out of his refrigerator earlier in the day, and started using it a few hours after he took it out. Had high post prandials that did not respond as usual to correcting. He had enough experience to wonder if perhaps something was wrong with his new insulin, so he thought he’d try another vial. He saw it was frozen. He had put the two vials at the back, where for many refrigerators it is colder. He thought back and wondered if the first vial looked any different, but remembered, he did not look closely at it.

Does insulin cause more deaths and cardiovascular outcomes than GLP-1 agonist receptors?

Recently Beta Bionics, the makers of the iLet artificial pancreas, reached a significant milestone: raising $1 million through online public fundraising. It is no longer a question of if an artificial pancreas will exist, but of when it will become commercially available. With every major insulin pump company working in this area, along with many startups, patients will not just have one system, but several they can chose from.